Eden Research plc · LSE:EDEN
Eden Research — Shareholder Meeting (2016)
24 slides from Eden Research's shareholder meeting presentation, 2016
Slide 1: The Natural Solution
—-D=N THE NATURAL SOLUTION
Slide 2: Overview
Overview Our vision is to be the leader in naturally-derived bioactive products enabled or enhanced by our novel encapsulation and delivery technologies Commercial sales have commenced and the company’s commercial pipeline is robust Eden has regulatory clearance for its first product in multiple cou
Slide 3: Financial Results 2015
Financial Results 2015 ● Revenue increased to £0.9m (2014 - £0.1m) ● Operating loss reduced to £1.1m (2014 - £1.7m) ● Operating loss (excluding Share Based Payment Charge of £0.25m and Amortisation of £0.66m) reduced to £0.2m in 2015 (2014 - £0.9m) ● Loss per share of 0.68p (2014 - 2.36p) 3
Slide 4: Financial Results 2015
Financial Results 2015 ● Cash at year end £0.15m (2014 - £0.4m) ● Placing in March 2016 of £2.6m ● New institutional investors ● Participation from multiple existing institutional shareholders ● Net liabilities at year end £0.44m (2014 – current assets £0.02m) ● Net assets at year end £6.0m (2014 -
Slide 5: Operational Highlights 2015
Operational Highlights 2015 ● Annex III Registration by zRMS (Malta) ● Annex III Registration in Greece and Bulgaria ● Annex IV Listing (exempt from maximum residue levels) ● New Evaluation agreements: ● Eastman – nematicide “B2Y” ● Sipcam (IT and ES) - new products ● New evaluations in South Americ
Slide 6: Post-Period Highlights
Post-Period Highlights ● Registration of 3AEY in Spain, Italy and Bulgaria ● Initiation of IV collaboration ● IP sourcing focussed on protecting work-arounds and new product concepts ● New collaboration with a leading a.i. producer ● Co-encapsulation of their proprietary active ingredient ● Ongoing
Slide 7: Post-Period Highlights
Post-Period Highlights ● Evaluation in new European countries ● Botrytis, powdery mildew and apple scab ● Poland, Czech Republic, Hungary, German, Slovakia ● Successful trials in Australia - Botrytis ● Molluscicide small scale trial ● Appointment of Stähler – Botrytis, Switzerland ● Exclusive distri
Slide 8: Product Launches 2016
Product Launces 2016 —d —d = — — — THE NATURAL SOLUTION LOGY a. ali [MEVALONE cs|
Slide 9: 2016 Focus
2016 Focus ● Nematicide deal completion ● Partnerships for 3AEY in key new territories ● Regulatory strategy and expansion ● Pursue collaboration with the majors ● Strengthening the team: Commercial, Regulatory, Technical ● Supply chain and commercialisation partnerships ● Regulatory submission in h
Slide 10: Optimising the business model
Optimising the business model • Typical gross margin: 30% Distributor • SP: €18.85 / litre Marketing and • Typical gross margin: 45% • SP of €14.50 / litre Sales Partner Formulator and • Typical gross margin: 50% • SP of €10 / litre Producer • Typical royalty on net sales: IP Owner and of 10 to 15%
Slide 11: Optimising the business model
Optimising the business model Licensing Product sales • All manufacturing, distribution and • Higher net income derived from logistics responsibilities are with the product sales (see example below) licensee • Higher level of control over know- • No funding required for cash to cash how and IPR cycl
Slide 12: Longer term vision
Longer term Expand beyond plant protection products vision • Animal health, food and beverages, human health and personal care Build internal resources where essential (project management, business development) Own registrations and leverage Focus on long term top line growth 12
Slide 13: Summary
Summary Natural chemistries create environmentally sustainable products and support sustainable agriculture Potential to enhance and extend patent life for existing commercial products Commercial sales have commenced and pipeline is robust Regulatory clearance secured for first product in multiple t
Slide 14: Disclaimer
• The content of information contained in these slides and the accompanying verbal presentation (together, the “Presentation”) has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”). Reliance upon this Presentation for the purpose of
Slide 15: The Natural Solution
—-D=N THE NATURAL SOLUTION
Slide 16: Non-Executive Directors
Non-Executive Tom Lupton - Chairman Directors Tom studied Agriculture and Forest Sciences at Oxford University, and spent 23 years working with the Commonwealth Development Corporation developing and managing large agribusiness companies in Southern Africa, culminating in being Managing Director of
Slide 17: Executive Directors
Executive Sean Smith – Chief Executive Officer Directors Sean has a bachelors degree in microbiology and over 25 years of experience in the speciality chemicals and industrial biotechnology industries. He has held senior commercial leadership roles ranging from sales and marketing to business manage
Slide 18: Key Staff
Key Staff Dr Gary Ostroff - Chairman of Scientific Advisory Board A microbiologist with over 20 years of research and development (R&D) experience in the biopharmaceutical, functional food and dietary supplement industries. He has served as Vice President of R&D for several US companies, including B
Slide 19: Eden by numbers
Eden by numbers current trials on £12 12 million active 5 evaluation continents invested in IP agreements & registrations 120+ 8 44 granted and active out- countries with pending license IP protection patents agreements 19
Slide 20: Eden's current target markets
Eden’s current target markets Biopesticides – Projected to be worth $6.9 billion by 2020 • Fungicides: Botrytis, powdery mildew, downy mildew • Molluscicides: slug and snail treatment • Insecticides: mites and white flies Conventional pesticides – Projected value of $76.8 billion by 2020 • Co-encaps
Slide 21: Untapped opportunity
Untapped The impact of product regulation in the EU: opportunity • It is estimated that the changes will reduce UK agriculture’s Gross Value Added (GVA) by about £1.6bn per annum – a drop of 20% on the 5-year average (2009-2013). • There are 87 active ingredients that are at medium or high risk of b
Slide 22: Our technology
Eden own the patents behind the “GO-E” delivery Our technology technology GO-E is a natural microencapsulation system: enables slow release and improved bioavailability of active substances such as terpenes and/or synthetic compounds The microcapsules are derived from yeast cells; a waste product fr
Slide 23: Terpene based products
Terpene based products Well-documented biocidal activity but difficult to use commercially due to their inherent volatility GO-E system allows these volatile active substances to be delivered to their target in a controlled manner, over time Using GO-E, Eden and its partners have been able to create
Slide 24: Product pipeline
Product pipeline Mevalone (3AEY): Botrytis (Grapes & SF, Powdery Mildew, GH Vegetable) B2Y: Nematodes, protected crops, outdoor vegetable 2EY: Powdery Mildew, outdoor vegetables Plant Protection G3Y 115: Molluscicide Insecticide: White fly, spider mites Co-encapsulation of synthetic pesticides Compa